Innovative immunotherapies in Oncology
Developing first-in-class biologics designed to overcome previously unaddressed immune evasion mechanisms.
Novel approaches for immune-mediated diseases
Advancing novel drugs that target key pathological pathways in a differentiated approach to restore immune homeostasis
Pipeline
Biond’s pipeline includes three clinical-stage oncology programs, alongside a portfolio of discovery and preclinical programs in immune-mediated diseases.
Our oncology pipeline features first-in-class Phase 2 and Phase 1 programs targeting key pathological pathways:
- BND-22 – anti-ILT2 (LILRB1) antibody, advancing in a Phase 2 study
- BND-67 – anti-CD28 shedding antibody, Phase 1 study underway
- BND-35 – a blocking anti-ILT3 (LILRB4) antibody
Our immune-mediated disease pipeline includes novel programs in discovery and preclinical stages, focused on innovative approaches to modulate the immune system.
Products
BND-22, is a Phase 2 first-in-class Immunoglobulin-Like Transcript 2 (ILT2) blocking antibody, with efficacy in solid tumors particularly in CRC and cholangiocarcinoma patients in combination with either anti-PD-1 agents or cetuximab, including in patients who had relapsed on cetuximab and presented with liver metastases. Currently in an ongoing Phase 2 study at MD Anderson in CRC, cholangiocarcinoma, and ovarian cancer.
BND-67, is a first-in-class antibody-based therapy, for preventing pathological CD28 shedding in cancer patients. BND-67's unique mechanism enhances effector T-cell activity while selectively inhibiting regulatory T-cells, offering a differentiated and highly targeted approach to drive potent anti-tumor immunity. The Phase 1 study is evaluating the safety and efficacy of BND-67 in patients with immunogenic tumors that have previously relapsed on T-cell activating therapies.
BND-35, is an innovative antibody targeting the Immunoglobulin-Like Transcript 3 (ILT3) receptor, in development for the treatment of solid tumors known to have a suppressive tumor microenvironment (TME). BND-35 was shown to be safe with no dose limiting toxicities as monotherapy in the dose escalation trial